For most of the history of drug development, the first real test of a new medicine happened inside an animal. A mouse, a rat, sometimes a dog would receive a candidate compound, and its response would decide whether the drug advanced toward human trials. The method is old, slow, and, by the industry’s own numbers, badly unreliable. Roughly 90 percent of drugs that clear animal testing go on to fail in human trials. A Philadelphia-founded company now operating south of San Francisco is betting that the fix is not a better animal but a different substrate entirely, and on August 12 it announced what it calls the world’s largest human biological datacenter.
What Vivodyne actually built
The company, Vivodyne, has assembled twelve robotic laboratories it refers to as HIVEs. Each is roughly the size of a wardrobe, and inside, automated systems grow living human tissue and run controlled experiments on it around the clock. The stated capacity is striking. The facility can produce about 3.1 million large human tissues per year and run trials on them, a throughput the company estimates at roughly twice the scale of all United States clinical trials combined.
The tissues are not simple cell cultures. Vivodyne grows more than twenty types of human organ tissue, including liver, lung, gut, kidney, pancreas, bone marrow, eyes, and lymph nodes, along with diseased versions modeling fibrosis, solid tumors, inflammation, metabolic disorders, and vascular disease. The cells are typically taken from ordinary human blood draws, then coaxed to grow on what the company calls a TissueDisk, a wafer-scale biological chip that hosts hundreds of tissues at once. On these chips the cells self-assemble into structures complete with blood vessels and immune cells, reproducing some of the behavior of the organ they came from.
The point is the data, not the tissue
A pile of lab-grown organs would be a laboratory curiosity. What turns it into a datacenter is the scale and the standardization. Because every tissue is grown and tested by the same robotic line, the results become comparable in a way that hand-run wet-lab experiments rarely are. Vivodyne can dose these tissues with tens of thousands of therapeutic compounds at the same time, across many organ types in parallel, and record how each responds.
That volume of clean, structured measurement is what the company is really after. It describes the output as the foundation for a world model of human biology, borrowing a phrase from artificial intelligence, where a model learns the underlying rules of a system well enough to predict how it will behave under new conditions. The same reinforcement learning techniques that trained large language models can, in principle, be applied here, with the AI proposing experiments, reading the results, and designing the next round. The physical lab becomes the training environment, and human tissue becomes the ground truth.
Chief executive and co-founder Andrei Georgescu framed the ambition in blunt terms, arguing that superintelligence in biology is needed more than ever because the industry is running out of diseases curable with the simple, single-target medicines of today. On the case against the status quo he was equally direct, suggesting that the failure rate from animals is so high that any alternative will quickly dominate.
Why now
Two things make this more than a well-funded science project. The first is regulatory. The FDA Modernization Act, passed in 2022, removed the longstanding requirement that a drug be tested in animals before it can enter human trials. That change opened the door for human-tissue platforms to stand on their own rather than as a supplement. The second is commercial traction. Vivodyne says eight major pharmaceutical companies have already paid for early access to the platform, which suggests the industry is willing to test the claim with real budgets.
The speed argument is concrete. The company says its automated tissues can run through 25 test cycles in the time it takes to breed and study a single batch of genetically modified mice, and it claims its platform can be up to a thousand times larger than competing human-tissue systems. Those numbers deserve independent scrutiny, and the harder proof, whether models trained on this data actually predict human trial outcomes better than the old pipeline, will take years to establish. Growing tissue that behaves like an organ is not the same as capturing a whole body, and immune and multi-organ effects remain difficult to reproduce on a chip.
The R&D takeaway
The interesting move here is not the robots or even the tissue. It is the reframing of biology as an industrial data problem. For decades, the bottleneck in drug discovery was not a shortage of ideas but a shortage of trustworthy experiments, each one slow, costly, and hard to compare with the next. Vivodyne’s bet is that if you standardize the experiment and run it millions of times, the raw material stops being tissue and becomes data at a scale that a model can learn from. That is the pattern worth watching across R&D. When a field’s progress is gated by the cost and inconsistency of its experiments, the breakthrough often comes from whoever industrializes the experiment itself, turning a craft into a production line and, with it, a dataset. The teams that reach that point first tend to set the pace for everyone who follows.
Until next time, keep questioning, and keep building.
The R&D Innovate desk
Sources
- Vivodyne launch announcement, August 12, 2026, GEN
- “The world’s largest biological datacenter could help make animal testing obsolete,” Fast Company
- Vivodyne company statements and prior funding coverage, Business Wire